Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma. Despite aggressive therapy, patients with metastatic or relapsed disease experience dismal outcomes and novel therapies are urgently needed. In this study, we evaluated expression of disialoganglioside (GD2), a cell surface antigen with therapeutic implication, in 16 RMS patient samples. Scoring revealed GD2 positivity in 25% of the samples. These data suggest that a small subset of RMS tumors express GD2, which may be a therapeutic target in these patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MPH.0000000000001311 | DOI Listing |
Publication Analysis
Top Keywords
disialoganglioside gd2
8
gd2 expression
4
expression pediatric
4
pediatric rhabdomyosarcoma
4
rhabdomyosarcoma case
4
case series
4
series review
4
review literature
4
literature rhabdomyosarcoma
4
rhabdomyosarcoma rms
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!